摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 2-((3aS,6R,6aR)-6-(azidomethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)acetate

中文名称
——
中文别名
——
英文名称
methyl 2-((3aS,6R,6aR)-6-(azidomethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)acetate
英文别名
methyl 2-[(3aR,4R,6aS)-4-(azidomethyl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]acetate
methyl 2-((3aS,6R,6aR)-6-(azidomethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)acetate化学式
CAS
——
化学式
C11H17N3O5
mdl
——
分子量
271.273
InChiKey
IZIDGUXJJBSKGK-ABONGIHLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    19
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.91
  • 拓扑面积:
    68.4
  • 氢给体数:
    0
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] NOVEL HAMAMELITANNIN ANALOGUES AND USES THEREOF<br/>[FR] NOUVEAUX ANALOGUES DU HAMAMÉLITANNIN ET LEURS UTILISATIONS
    申请人:UNIV GENT
    公开号:WO2018065387A1
    公开(公告)日:2018-04-12
    The present invention relates to hamamelitannin analogues, pharmaceutical compositions comprising the same, and combinations thereof with anti-microbial agents such as antibiotics or disinfectants. It in particular relates to the use of the compounds, compositions and combinations according to this invention in human or veterinary medicine, more in particular for use in the prevention and/or treatment of bacterial infections, such as Staphylococcus aureus infections, in humans or animals.
    本发明涉及金缕梅鞣质类似物、包含其的药物组合物,以及与抗微生物药剂(如抗生素或消毒剂)的组合物。特别涉及本发明中的化合物、组合物和组合物在人类或兽医学中的使用,更具体地用于预防和/或治疗细菌感染,如金黄色葡萄球菌感染,在人类或动物身上。
  • Compounds, linker-drugs and ligand-drug conjugates
    申请人:Industrial Technology Research Institute
    公开号:US10233212B2
    公开(公告)日:2019-03-19
    A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), R1, R2 and R3 are each, independently, hydrogen, amino, nitro, halogen, hydroxyl, C1-C6 alkoxy, carboxylic acid, C1-C6 alkoxycarbonyl, C1-C6 amino, C1-C6 aminocarbonyl, C1-C6 alkyl, branched C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 heterocyclic, aryl or heteroaryl, provided at least one of R1 and R3 is an amino group. A linker-drug and a ligand-drug conjugate including the compound are also provided.
    本发明提供了式 (I) 的化合物或其药学上可接受的盐或溶液。在式 (I) 中,R1、R2 和 R3 各自独立地为氢、氨基、硝基、卤素、羟基、C1-C6 烷氧基、羧酸、C1-C6 烷氧羰基、C1-C6 氨基、C1-C6 氨基羰基、C1-C6 烷基、支链 C1-C6 烷基、C1-C6 环烷基、C1-C6 杂环基、芳基或杂芳基,条件是 R1 和 R3 中至少有一个是氨基。还提供了包括该化合物的连接体-药物和配体-药物共轭物。
  • COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES
    申请人:Industrial Technology Research Institute
    公开号:US20180016300A1
    公开(公告)日:2018-01-18
    A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), R1, R2 and R3 are each, independently, hydrogen, amino, nitro, halogen, hydroxyl, C1-C6 alkoxy, carboxylic acid, C1-C6 alkoxycarbonyl, C1-C6 amino, C1-C6 aminocarbonyl, C1-C6 alkyl, branched C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 heterocyclic, aryl or heteroaryl, provided at least one of R1 and R3 is an amino group. A linker-drug and a ligand-drug conjugate including the compound are also provided.
  • US8440851B2
    申请人:——
    公开号:US8440851B2
    公开(公告)日:2013-05-14
  • Novel hamamelitannin analogues for the treatment of biofilm related MRSA infections–A scaffold hopping approach
    作者:Arno Vermote、Gilles Brackman、Martijn D.P. Risseeuw、Tom Coenye、Serge Van Calenbergh
    DOI:10.1016/j.ejmech.2016.10.056
    日期:2017.2
    Hamamelitannin (HAM) was recently identified as an antimicrobial potentiator for conventional antibiotics towards Staphylococcus aureus. This paper describes the synthesis and biological evaluation of novel hamamelitannin analogues with alternative central scaffolds. Via a ligand-based approach, several interesting compounds with improved synthetic accessibility were identified as potentiators for vancomycin
    抗菌研究越来越集中在耐药性和生物膜形成的问题上。金缕梅宁(HAM)最近被确定为针对金黄色葡萄球菌的常规抗生素的抗菌增效剂。本文描述了具有替代中心支架的新型金缕梅宁类似物的合成和生物学评估。通过基于配体的方法,几种具有改善的合成可及性的有趣化合物被确定为万古霉素在MRSA感染治疗中的增强剂。
查看更多